A retrospective study to assess safety of nivolumab for treatment of cancer in liver transplant recipients
Latest Information Update: 29 Jan 2021
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Cancer
- Focus Adverse reactions
- 29 Jan 2021 New trial record